Claims for Patent: 8,501,792

Summary for Patent: 8,501,792

Title:	Treating cancer with desthiazolyl ritonavir
Abstract:	Treatment of cancer includes administering a compound of formula I, for example des-ritonavir, to a subject. In particular, treatment of breast cancer is described.
Inventor(s):	Potter; David A. (St. Louis Park, MN), Milani; Monica (Frejus, FR), Srirangam; Anjaiah (Lexington, MA), Mitra; Ranjana (Las Vegas, NV), Remmel; Rory P. (Minneapolis, MN)
Assignee:
Application Number:	12/867,845
Patent Claims:	1. A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of formula I: ##STR00009## wherein each R is independently H or C.sub.1-6 alkyl, or a pharmaceutically acceptable salt form thereof. 2. The method of claim 1, wherein the compound of formula I is: ##STR00010## or a pharmaceutically acceptable salt form thereof. 3. The method of claim 1, wherein the subject is a human. 4. The method of claim 1, wherein the cancer is selected from: bladder cancer, brain cancer, breast cancer, colorectal cancer, cervical cancer, gastrointestinal cancer, genitourinary cancer, head and neck cancer, hematologic cancer, lung cancer, ovarian cancer, prostate cancer, renal cancer, skin cancer, and testicular cancer. 5. The method of claim 4, wherein the cancer is breast cancer. 6. The method of claim 5, wherein the breast cancer is ER.sup.+ breast cancer. 7. The method of claim 5, wherein the breast cancer is her2.sup.- or her2.sup.+ breast cancer. 8. The method of claim 5, wherein the breast cancer is triple negative breast cancer. 9. The method of claim 1, wherein the subject is post-menopausal. 10. The method of claim 1, wherein the subject has a cancer associated with resistance to a known anticancer drug regime. 11. The method of claim 10, wherein the anticancer drug regime is selected from one or more of Taxol, Herceptin, Avastin, 5-fluouracil and epirubicin. 12. The method of claim 10, wherein the cancer comprises cells that express a P glycoprotein (MDR), a multidrug resistance-associated protein (MRP), or a breast cancer resistance protein (BCRP). 13. A pharmaceutical composition comprising a compound of formula I: ##STR00011## wherein each R is independently H or C.sub.1-6 alkyl, or a pharmaceutically acceptable salt form thereof. 14. The composition of claim 13, wherein the composition further comprises a carrier, excipient, or diluent. 15. The composition of claim 13, wherein the composition further comprises a pain relief agent, an antinausea agent, ritonavir, or an additional anticancer agent. 16. The method of claim 4, wherein the hematologic cancer is acute myeloid leukemia.

Details for Patent 8,501,792

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2028-02-19
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2028-02-19
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-02-19